Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GDRX Stock Forecast 2026-2027
$3.04
Current Price
$999.09M
Market Cap
Buy 5
Hold 8
Sell 2
Wall St Analyst Ratings
Distance to GDRX Price Targets
+31.6%
To High Target of $4.00
-1.3%
To Median Target of $3.00
-26.0%
To Low Target of $2.25
GDRX Price Momentum
+0.3%
1 Week Change
+14.7%
1 Month Change
-37.1%
1 Year Change
+12.2%
Year-to-Date Change
-47.7%
From 52W High of $5.81
+71.8%
From 52W Low of $1.77
📊 TOP ANALYST CALLS
Did GDRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if GoodRx is one of their latest high-conviction picks.
Latest GDRX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, GDRX has a neutral consensus with a median price target of $3.00 (ranging from $2.25 to $4.00). The overall analyst rating is Buy (6.9/10). Currently trading at $3.04, the median forecast implies a -1.3% downside. This outlook is supported by 5 Buy, 8 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Daniel Grosslight at Citigroup, projecting a 31.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GDRX Analyst Ratings
5
Buy
8
Hold
2
Sell
GDRX Price Target Range
Low
$2.25
Average
$3.00
High
$4.00
Current: $3.04
Latest GDRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GDRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2026 | Citigroup | Daniel Grosslight | Buy | Maintains | $4.00 |
| May 11, 2026 | TD Cowen | Charles Rhyee | Buy | Maintains | $4.00 |
| Mar 4, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Mar 3, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Mar 2, 2026 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Feb 27, 2026 | Mizuho | Neutral | Maintains | $N/A | |
| Feb 27, 2026 | JP Morgan | Neutral | Downgrade | $N/A | |
| Jan 22, 2026 | Jefferies | Hold | Downgrade | $N/A | |
| Jan 9, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Dec 18, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Dec 9, 2025 | Barclays | Underweight | Initiates | $N/A | |
| Nov 11, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Nov 10, 2025 | TD Cowen | Buy | Maintains | $N/A | |
| Nov 6, 2025 | UBS | Neutral | Maintains | $N/A | |
| Nov 6, 2025 | Mizuho | Neutral | Maintains | $N/A | |
| Aug 11, 2025 | UBS | Neutral | Maintains | $N/A | |
| May 13, 2025 | UBS | Neutral | Maintains | $N/A | |
| May 9, 2025 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Apr 29, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Apr 10, 2025 | Truist Securities | Hold | Maintains | $N/A |
GoodRx Holdings, Inc. Class A Common Stock (GDRX) Competitors
The following stocks are similar to GoodRx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GoodRx Holdings, Inc. Class A Common Stock (GDRX) Financial Data
GoodRx Holdings, Inc. Class A Common Stock has a market capitalization of $999.09M with a P/E ratio of 49.2x. The company generates $787.89M in trailing twelve-month revenue with a 2.6% profit margin.
Revenue growth is -4.4% quarter-over-quarter, while maintaining an operating margin of +7.2% and return on equity of +3.2%.
Valuation Metrics
Market Cap
$999.09M
Enterprise Value
$1.30B
P/E Ratio
49.2x
PEG Ratio
-0.5x
Price/Sales
1.3x
Growth & Margins
Revenue Growth (YoY)
-4.4%
Gross Margin
+89.6%
Operating Margin
+7.2%
Net Margin
+2.6%
EPS Growth
-89.4%
Financial Health
Cash/Price Ratio
+22.9%
Current Ratio
1.5x
Debt/Equity
87.0x
ROE
+3.2%
ROA
+3.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
GoodRx Holdings, Inc. Class A Common Stock (GDRX) Business Model
About GoodRx Holdings, Inc. Class A Common Stock
What They Do
Offers digital tools for prescription price comparison.
Business Model
The company makes money by aggregating prescription pricing data and providing consumers access to discounts at pharmacies. It also generates revenue through subscription services, solutions for pharmaceutical manufacturers, and telehealth offerings via its GoodRx Care platform.
Additional Information
GoodRx Holdings, Inc. was founded in 2011 and is headquartered in Santa Monica, California. It plays a significant role in enhancing price transparency and affordability in the U.S. prescription market and also addresses the pet health segment with prescription-related products and services for animals.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
697
CEO
Ms. Wendy Barnes
Country
United States
IPO Year
2020
Website
www.goodrx.comGoodRx Holdings, Inc. Class A Common Stock (GDRX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
GoodRx (GDRX) Upgraded to Buy: What Does It Mean for the Stock?
GoodRx (GDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Jul 08, 2026
By Zacks Equity Research
Tale of the Tape
GDRX or HQY: Which Is the Better Value Stock Right Now?
GDRX vs. HQY: Which Stock Is the Better Value Option?
Jul 08, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
GoodRx Holdings, Inc. will release its Q2 2026 financial results on August 5, 2026, after market close, followed by a conference call on August 6 at 5:00 a.m. PT.
Why It Matters
GoodRx's upcoming financial results and conference call will provide insights into its performance and strategy, impacting investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zacks emphasizes its Rank system, focusing on earnings estimates and revisions to identify strong stocks, while also monitoring value, growth, and momentum trends.
Why It Matters
The emphasis on earnings estimates and revisions signals potential stock performance, guiding investors toward high-quality picks based on current market trends.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
GoodRx (GDRX) has been upgraded to a Zacks Rank #2 (Buy), indicating growing optimism about its earnings prospects, which may lead to a potential increase in stock price.
Why It Matters
GoodRx's upgrade to a Zacks Rank #2 indicates increased confidence in its earnings potential, potentially attracting more investors and driving up stock prices.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY) are two medical services stocks attracting investor interest. A comparison is underway to determine which offers better value.
Why It Matters
The comparison of GoodRx and HealthEquity highlights potential investment opportunities, guiding value investors to make informed decisions on stock selection in the medical services sector.
Source: Zacks Investment Research
Market Sentiment:
Neutral
GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs
1 month ago
Quick Summary
GoodRx launched GoodRx Companion, a $14.99/month subscription service offering access to low-cost medications, online care visits, and healthcare savings, addressing rising out-of-pocket costs.
Why It Matters
GoodRx's launch of a subscription service addresses rising healthcare costs, potentially increasing user engagement and revenue, which could positively impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
GoodRx Holdings reports a 4% Y/Y revenue decline and EBITDA margin compression to 18.5%. Legacy business erosion expected through 2026; base DCF value is $2.49/share, indicating downside risk.
Why It Matters
GoodRx's declining legacy business and lower profitability from Pharma Direct signal revenue challenges ahead, impacting valuations and increasing downside risk for investors.
Source: Seeking Alpha
Market Sentiment:
Negative
Frequently Asked Questions About GDRX Stock
What is GoodRx Holdings, Inc. Class A Common Stock's (GDRX) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, GoodRx Holdings, Inc. Class A Common Stock (GDRX) has a median price target of $3.00. The highest price target is $4.00 and the lowest is $2.25.
Is GDRX stock a good investment in 2027?
According to current analyst ratings, GDRX has 5 Buy ratings, 8 Hold ratings, and 2 Sell ratings. The stock is currently trading at $3.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GDRX stock?
Wall Street analysts predict GDRX stock could reach $3.00 in the next 12 months. This represents a -1.3% decrease from the current price of $3.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is GoodRx Holdings, Inc. Class A Common Stock's business model?
The company makes money by aggregating prescription pricing data and providing consumers access to discounts at pharmacies. It also generates revenue through subscription services, solutions for pharmaceutical manufacturers, and telehealth offerings via its GoodRx Care platform.
What is the highest forecasted price for GDRX GoodRx Holdings, Inc. Class A Common Stock?
The highest price target for GDRX is $4.00 from Daniel Grosslight at Citigroup, which represents a 31.6% increase from the current price of $3.04.
What is the lowest forecasted price for GDRX GoodRx Holdings, Inc. Class A Common Stock?
The lowest price target for GDRX is $2.25 from at , which represents a -26.0% decrease from the current price of $3.04.
What is the overall GDRX consensus from analysts for GoodRx Holdings, Inc. Class A Common Stock?
The overall analyst consensus for GDRX is neutral. Out of 3 Wall Street analysts, 5 rate it as Buy, 8 as Hold, and 2 as Sell, with a median price target of $3.00.
How accurate are GDRX stock price projections?
Stock price projections, including those for GoodRx Holdings, Inc. Class A Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 2:46 AM UTC